A phase 2 trial of ABP-745 for ASCVD (atherosclerotic cardiovascular disease).
Latest Information Update: 24 Nov 2025
At a glance
- Drugs ABP-745 (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Therapeutic Use
Most Recent Events
- 24 Nov 2025 New trial record
- 28 Oct 2025 According to Atom Therapeutics media release, a phase 2 study of ABP-745 for ASCVD (atherosclerotic cardiovascular disease) is planned to start in early 2026.